IP Library Granted Patent US 9,937,137
Granted Patent B2
US 9,937,137 · App. 14/764,944 · Granted Apr 10, 2018

Magnesium compositions and uses thereof for cancers

Inventors: Guosong Liu (Sunnyvale, CA); Fei Mao (Fremont, CA)
Assignee: Neurocentria, Inc.
A61K31/191A61K31/195A61K33/06A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,937,137
App. No.
14/764,944
Granted
Apr 10, 2018
Kind
B2
Abstract

Compositions and methods that are useful for treating a subject suffering from one or more cancers are provided herein. Such compositions and methods can contain an effective amount of magnesium threonate to be used to support or improve the mental state of a subject. The composition and methods comprising magnesium threonate can also be used to support a cancer treatment.

Claims (16)

1. A method of treating a solid or cystic tumor in a subject in need thereof, the method comprising:

administering to the subject in need thereof a pharmaceutical composition comprising an effective amount of magnesium threonate, thereby treating the solid or cystic tumor in the subject in need thereof, wherein the solid or cystic tumor is a cancer selected from the group consisting of: breast cancer, lung cancer, prostate cancer, gastric cancer, head & neck cancer, melanoma, bladder cancer, neuroendocrine cancer, squamous carcinoma, cervical cancer, vulvar cancer, thyroid cancer, pancreatic cancer, renal cancer, esophageal cancer, rectal cancer, penile cancer, multiple myeloma, Merkel cell tumors, ovarian cancer and colorectal cancer.

2. The method of claim 1 , further comprising treating the subject with a cancer therapeutic.

3. The method of claim 1 , wherein the pharmaceutical composition further comprises one or more anti-cancer agents.

4. The method of claim 1 , wherein the subject suffering from the solid or cystic tumor also suffers from depression, anxiety, dementia, insomnia, cognitive impairment, memory function decline, learning capacity decline, migraine, mood swing, hypertension, attention deficit hyperactivity disorder, Alzheimer's disease or Parkinson's disease.

5. The method of claim 1 , wherein said administering of the pharmaceutical composition is effective in improving mental state of said subject.

6. The method of claim 1 , wherein the pharmaceutical composition is administered orally.

7. The method of claim 1 , wherein the effective amount of magnesium threonate administered is in an amount of about 1.5 mg/kg of body weight/day to about 18 mg/kg of body weight/day.

8. The method of claim 1 , wherein the pharmaceutical composition is administered for at least about 1 month.

9. The method of claim 1 , wherein the pharmaceutical composition is administered for at least about 1 week.

10. The method of claim 1 , wherein said effective amount is an amount capable of achieving a physiological concentration of magnesium at 0.75 mM or above in serum, plasma, or cerebrospinal fluid.

11. The method of claim 1 , wherein said effective amount is an amount capable of increasing a physiological concentration of magnesium by at least 10% as compared to an initial level of magnesium prior to administration of it to said subject.

12. The method of claim 1 , wherein the pharmaceutical composition is contained in a foodstuff.

13. The method of claim 1 , wherein the effective amount of magnesium threonate is in an amount of less than 1.5 mg/kg of body weight/day.

14. The method of claim 1 , wherein the effective amount of magnesium threonate is in an amount of about 9 mg/kg of body weight/day to 18 mg/kg of body weight/day.

15. The method of claim 1 , wherein the effective amount of magnesium threonate is in an amount of more than 18 mg/kg of body weight/day.

Assignments (2)
CHANGE OF NAME Recorded Apr 19, 2016
From: MAGCEUTICS, INC.
To: NEUROCENTRIA, INC.
Reel/Frame 038315/0295 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2016
From: LIU, GUOSONG; MAO, FEI
To: MAGCEUTICS, INC.
Reel/Frame 037695/0547 →
Continuity (2)
Provisional Application 61800202 · Mar 15, 2013
Related Publication 20150366828A1 · Dec 24, 2015